BIAF News

The small-cap market is heating up with a fresh wave of catalysts, as several companies put major developments in front of investors. Among the names drawing attention are Aethlon Medical (NASDAQ:AEMD), NeOnc Technologies Holdings (NASDAQ:NTHI), bioAffinity Technologies (NASDAQ:BIAF), Turbo Energy (NASDAQ:TURB), and Datasea Intelligent Technology (NASDAQ:DTSS).

bioAffinity Technologies (NASDAQ:BIAF) is expanding the intellectual-property moat around its CyPath Lung diagnostic, adding a newly granted Hong Kong patent to a patent covering the technology in China. The move gives the company dual patent protection in two important Asian markets as it looks to expand the commercial potential of a noninvasive approach to lung-cancer detection.

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that the Hong Kong Intellectual Property Department has granted a patent for the Companys proprietary...

The biopharma trade has entered a fascinating stretch. Investors continue to focus heavily on the industry's giants, including Novartis (NYSE:NVS), Eli Lilly (NYSE:LLY), and Amgen (NASDAQ:AMGN), but the latest market action is a reminder that some of the biggest percentage moves in biotechnology can come from much smaller companies. That is where the bull case for looking beyond the mega-caps begins. 24/7 Market News has urged investors to broaden the lens to smaller companies including Tenon Medical (NASDAQ:TNON), NeOnc Technologies Holdings (NASDAQ:NTHI), Opus Genetics (NASDAQ:IRD), and bioAffinity Technologies (NASDAQ:BIAF). These companies share one potentially important characteristic: their valuations can be heavily influenced by discrete clinical, regulatory, commercial, or financing milestones.

Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF) stockread more...

The latest market developments are putting investors’ attention back on tangible catalysts: NeOnc Technologies Holdings (NASDAQ:NTHI) is pairing fresh institutional capital with encouraging NEO100 clinical data; Opus Genetics (NASDAQ:IRD) is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; bioAffinity Technologies (NASDAQ:BIAF) removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; Tenon Medical (NASDAQ:TNON) eliminated roughly $5.16 million of convertible-note obligations ahead of maturity; Sunation Energy (NASDAQ:SUNE) is positioned at the center of Suniva’s $835 million financing and planned expansion to 5.5 GW of U.S. solar-cell capacity; and The OLB Group (NASDAQ:OLB) is attempting to build a rebound momentum after recently hitting a new 52-week low and, yes, I know that’s a sixth company.

bioAffinity Technologies (NASDAQ:BIAF) removed one of the biggest overhangs facing its stock, announcing that Nasdaq confirmed the Company regained compliance with its listing requirements. The September 8 notice means BIAF’s common stock and warrants will continue trading on the Nasdaq Capital Market, while a previously scheduled Nasdaq Hearings Panel hearing has been canceled.

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has received written notice from The Nasdaq Stock Market LLC stating that the Company has...

Gainers Immuron (NASDAQ:IMRN) shares moved upwards by 48.2% to $1.65 during Friday's regular session. The market value of their outstanding shares is at $8.9 million. bioAffinity Technologies (NASDAQ:BIAF) sharesread more...